Sodium-Endothelial Function-CKD Study
Primary Purpose
Kidney Failure, Chronic
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Slow sodium
Sponsored by
About this trial
This is an interventional prevention trial for Kidney Failure, Chronic focused on measuring Endothelial dysfunction, ADMA, DDAH, Sodium
Eligibility Criteria
Inclusion Criteria: CKD Stages 2 and 3 [= calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by Cockcroft-Gault formula] 18 to 75 years old Exclusion Criteria: >3 g/24 hours of proteinuria Uncontrolled hypertension (systolic BP >160 mmHg, diastolic BP >100 mmHg on/off anti-hypertensive medication) Diabetes mellitus Tobacco smoking Total fasting cholesterol >6 mmol/L Uncontrolled heart failure or active IHD Chronic liver failure Active malignancy
Sites / Locations
- Blood Pressure Unit, Department of Cardiac & Vascular Sciences, SGUL
Outcomes
Primary Outcome Measures
Under conditions of high (vs. low sodium intake) ...
(i) The ratio [ADMA]urine:[DMA]urine is increased
(ii) [ADMA]plasma is increased
(iii) Endothelium-dependent vasodilatation is reduced
Secondary Outcome Measures
Full Information
NCT ID
NCT00141622
First Posted
August 31, 2005
Last Updated
May 14, 2007
Sponsor
St George's, University of London
Collaborators
British Heart Foundation, St. George's Hospital Charitable Foundation
1. Study Identification
Unique Protocol Identification Number
NCT00141622
Brief Title
Sodium-Endothelial Function-CKD Study
Official Title
Does Sodium Affect Endothelial Function in Individuals With Chronic Kidney Disease?
Study Type
Interventional
2. Study Status
Record Verification Date
August 2005
Overall Recruitment Status
Completed
Study Start Date
April 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
St George's, University of London
Collaborators
British Heart Foundation, St. George's Hospital Charitable Foundation
4. Oversight
5. Study Description
Brief Summary
Heart disease and stroke, known as cardiovascular disease, are major causes of death in people with chronic kidney disease. Abnormalities of a metabolic pathway called the "L-arginine-nitric oxide" pathway are thought to be particularly important in these people, and previous research in animals has suggested that sodium (salt) affects part of this metabolic pathway. The purpose of our research is to study the effects of sodium intake on the "L-arginine-nitric oxide" pathway, and on blood vessel function, in patients with kidney disease.
Detailed Description
Chronic kidney disease (CKD) is associated with abnormalities of endothelial function (EF) and nitric oxide (NO) synthesis, and it is proposed that the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) plays a central role. In man ADMA is largely metabolized by dimethylarginine dimethylaminohydrolase (DDAH), with some renal excretion occurring. Sodium inhibits DDAH expression in experimental animals and, given that CKD is frequently characterized by sodium retention, it would be interesting to study the effects of sodium loading on DDAH activity/expression, ADMA levels and EF in CKD patients.
To answer these questions, we have designed a double-blind cross-over study employing Slow Sodium (150 mmol/day) and placebo for seven days in individuals with mild-to-moderate CKD. Changes in the ratio of urinary ADMA to dimethylamine (DMA, an ADMA metabolite) will be used as an marker of DDAH activity/expression. ADMA will be measured by ELISA, DMA by high performance liquid chromatography, and EF by venous occlusion plethysmography.
We propose to test the following hypothesis; that in subjects with mild-to-moderate CKD under conditions of high sodium intake, as compared to low-normal sodium intake:
(i) The ratio [ADMA]urine:[DMA]urine is increased (ii) [ADMA]plasma is increased (iii) Endothelium-dependent vasodilatation is reduced
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Failure, Chronic
Keywords
Endothelial dysfunction, ADMA, DDAH, Sodium
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Slow sodium
Primary Outcome Measure Information:
Title
Under conditions of high (vs. low sodium intake) ...
Title
(i) The ratio [ADMA]urine:[DMA]urine is increased
Title
(ii) [ADMA]plasma is increased
Title
(iii) Endothelium-dependent vasodilatation is reduced
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
CKD Stages 2 and 3 [= calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by Cockcroft-Gault formula]
18 to 75 years old
Exclusion Criteria:
>3 g/24 hours of proteinuria
Uncontrolled hypertension (systolic BP >160 mmHg, diastolic BP >100 mmHg on/off anti-hypertensive medication)
Diabetes mellitus
Tobacco smoking
Total fasting cholesterol >6 mmol/L
Uncontrolled heart failure or active IHD
Chronic liver failure
Active malignancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy WR Doulton, BSc MRCP
Organizational Affiliation
SGUL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Blood Pressure Unit, Department of Cardiac & Vascular Sciences, SGUL
City
London
ZIP/Postal Code
SW17 0RE
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Sodium-Endothelial Function-CKD Study
We'll reach out to this number within 24 hrs